Dr. John E. Sylvester, MD

Dr. Sylvester practices at Genesiscare Usa of Florida in Cape Coral, Florida.

Dr. Sylvester's NPI, 1508880337, was assigned on July 26, 2006. Dr. Sylvester graduated from David Geffen School of Medicine at UCLA in 1984. Dr. Sylvester holds Florida license ME105971.

Dr. Sylvester's primary practice is Genesiscare Usa of Florida, at 1419 SE 8th Ter, Cape Coral, FL 33990 in Lee County. The practice phone is (239) 489-3420.

Dr. Sylvester's primary practice is Genesiscare Usa of Florida in Cape Coral, Florida. Dr. Sylvester is also affiliated with Grand Strand Medical Center. The medical group on file is GenesisCare. Dmand AI also links Dr. Sylvester to 1 more hospital, 3 medical groups, 2 group practices and clinics and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sylvester practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Sylvester's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Sylvester is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Sylvester's licenses on file in 5 states: Florida, New Jersey, South Carolina, Washington and California.

Dmand AI lists bladder cancer radiation and prostate cancer radiation among the conditions Dr. Sylvester treats.

CMS data shows 12,823 Medicare services from Dr. Sylvester across 26 procedure codes in 2024, for 411 Medicare patients. Medicare paid $2,129,133 for them.

CMS counts 411 Medicare patients who saw Dr. Sylvester in 2024. The largest group is 65 to 74, with 195 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Sylvester's median patient age at 74, with 18% women.

In 2024, Dr. Sylvester wrote 1,385 Medicare Part D claims for 453 patients. 88% of them were for generic drugs. CMS names the drug for 1,325 of them, across 13 drugs with 11 or more claims each, at $669,441 in total drug cost. In 2023, CMS named 1,307 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Sylvester for performance year 2024, reported individually. Dr. Sylvester accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sylvester as offering telehealth.

Dmand AI links 34 papers to Dr. Sylvester, published from 2006 to 2023. 2008 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms, Brachytherapy and Iodine Radioisotopes. Dr. Sylvester has published most often in Int J Radiat Oncol Biol Phys. Dr. Sylvester's most frequent co-authors are David C. Beyer, MD, Jeffrey A. Bogart, MD and Richard S. Hudes, MD.

Dmand AI links Dr. Sylvester to 2 clinical trials. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 225 general payments to Dr. Sylvester from 31 drug and device companies from 2016 to 2025. Ownership or investment make up the largest share, 47% of the total. Boston Scientific Corporation paid the most, $249,561.

Dmand AI lists 2 awards for Dr. Sylvester, most recently CMS Stage 1 EHR in 2014.

Dr. Sylvester graduated from David Geffen School of Medicine at UCLA in 1984.

Dr. Sylvester is in network with 18 carriers, including Elevance, Excellus BlueCross BlueShield and Aetna. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.